Physician profile
Andrea Stebel
NPI 1447258389
$485,888.58
in general payments reported to CMS, 2019-2025
28 companies · $20K in 2025
The $20K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159K · 2020: $16K · 2021: $79K · 2022: $75K · 2023: $80K · 2024: $57K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Consulting Fee: $32K · Travel and Lodging: $30K · Food and Beverage: $3,927 · Grant: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $90,750.00 |
| Consulting Fee | $31,822.50 |
| Travel and Lodging | $30,301.82 |
| Food and Beverage | $3,927.46 |
| Grant | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $355,490.19 | 2019-2025 | Verzenio |
| Celgene Corporation | $51,962.85 | 2019 | |
| Tersera Therapeutics LLC | $34,675.07 | 2019-2025 | Zoladex |
| Gilead Sciences, INC. | $16,940.86 | 2022-2023 | Trodelvy |
| Coherus Oncology, INC. | $8,265.56 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $7,403.52 | 2019-2025 | Enhertu, Lynparza |
| Eli Lilly and Company | $6,500.00 | 2023 | |
| Puma Biotechnology, INC. | $2,180.00 | 2020 | |
| Daiichi Sankyo INC. | $1,198.41 | 2021-2024 | Enhertu |
| Cepheid | $704.00 | 2020-2022 | |
| Amgen INC. | $81.57 | 2019 | |
| Merck Sharp & Dohme LLC | $71.19 | 2019-2020 | |
| Exelixis INC. | $66.05 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.59 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $29.45 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $29.41 | 2019 | |
| Abbvie INC. | $29.38 | 2019 | |
| Alexion Pharmaceuticals, INC. | $28.71 | 2019 | |
| Eisai INC. | $27.47 | 2019 | |
| Shire North American Group INC | $24.28 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.11 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $18.71 | 2019 | |
| Genzyme Corporation | $17.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.33 | 2019 | |
| Genentech USA, INC. | $16.71 | 2019 | |
| Pfizer INC. | $15.90 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.53 | 2019 | |
| Incyte Corporation | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Stebel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.